Tandem's Tubeless Pivot: Pharmacy Ramp and a 510(k) Submission Point to an Inflection
Q2 '26 shows rising gross margin, record pump shipments, and a stride toward the AdaNet fully closed loop — the real question is how fast PayGo scales.
TNDM · Earnings Call · 2026-08-06
Today, we are closer to this vision than ever and excited to begin sharing more details.
That was John Sheridan, Tandem's CEO, on the Q2 2026 call — a vision of an artificial pancreas, anchored by the AdaNet fully closed-loop algorithm now entering a pivotal study. But the more immediate catalyst is shorter-term: the company shipped a record 33,000 pumps worldwide (up 10% YoY), sales rose 6% to $255 million, and gross margin hit 57%, the second-highest quarter in company history. The stock, though still down ~88% from 2014 highs, has rebounded 45% in the last six weeks as investors bet that the PayGo pharmacy transition and the newly filed Mobi tubeless will unlock an inflection.
The centerpiece is pharmacy. In the first full quarter of PayGo, U.S. pharmacy pump shipments reached 10% of total shipments, and formulary coverage sits at 45% — near the top of this year's target. "We are actually very pleased with the early PAYGO experience," Sheridan said in Q&A, noting it "reinforces our conviction that this is an important and meaningful opportunity for the business." The economics are attractive: “In this first full quarter under the PAYGO structure, pharmacy pump shipments were approximately 10% of total shipments.” — Leigh A. Vosseller, Management · 2026-08-06 More importantly, management disclosed that the average monthly ASP for pharmacy-supplied consumables is running above the $350 modeling assumption, suggesting upside to the revenue engine. This is a strategic pivot from the traditional DME model. As Leigh Vosseller had noted on the prior call, the shift is "an impactful change in the business. We're very excited about it. When you look at the revenue numbers, the revenue numbers are impacted by the headwinds from the pricing that comes along with PayGo." (Feb 2026) The company is now seeing the early benefits.
On the new-start side, the trajectory is improving. U.S. new starts were nearly flat year over year but stepped up more than 20% sequentially, and — critically — MDI conversions grew mid-single digits and now represent ~70% of new starts. “We have seen improvement in the new start trajectory with Q2 new starts nearly flat to last year, but stepping up impressively by more than 20% from Q1.” — Leigh A. Vosseller, Management · 2026-08-06 This is a genuine operational pivot, and it directly supports the company's confidence in returning to new-start growth.
Beyond the channel, the product pipeline is full. The FDA submission for Mobi tubeless — the world's first extended-wear patch with a 7-day set — positions Tandem to compete in the high-growth tubeless segment, which John describes growing at over 20% versus mid-single digits for tubed pumps. The AID system pipeline extends to ADA-Net, with an IDE approved and a pivotal study expected later this year. Also notable is the global channel strategy: direct launches in the UK, Switzerland, Austria, and France later this year, which should lift international ASPs and margins.
The type 2 opportunity remains the next leg. The company is selective in patient acquisition, and type 2 attrition is stable. The C-peptide decision from CMS, expected this August, could be a significant tailwind. As Sheridan said, "We expect it to be positive. I think any steps in a positive direction will be good for people with type 2." The combination of pharmacy access, FreeStyle Libre 3, and the tubeless form factor could drive a step-change in adoption.
Financially, the company is deleveraging and improving efficiency. Q2 gross margin expanded 5 points year over year to 57%, while adjusted EBITDA margin reached 3% — positive for the fourth consecutive quarter. Gross margin rose to 57% on pricing appreciation and Mobi scale. Operating expenses stayed flat as stock-based comp fell to $16M, and cash remains healthy at $456M despite investments in the CRM system, the Roche settlement, and a strategic stake in Secur. The company reaffirmed 2026 sales of $1.065–1.085B and gross margin of 56–57%, with Q4 exit gross margin expected near 60%.
Risks remain: the infusion set shortage from a key supplier had a greater-than-expected impact internationally, and the Q3 gross margin guide of 56% reflects the pump headwind from pharmacy. But the directional story is clear. As the company executes its global channel strategy and scales pharmacy adoption, the mix shift toward higher-recurring-revenue customers should smooth the historical seasonality and drive sustained margin gains. Tandem is no longer a story about survival; it is a story about a targeted execution path to profitable growth.